Healthcare M&A Holds Strong Mid-2026 Momentum as AI and $11.75 Billion Deals Drive Activity
Updated
Updated · JP Morgan · Jun 26
Healthcare M&A Holds Strong Mid-2026 Momentum as AI and $11.75 Billion Deals Drive Activity
3 articles · Updated · JP Morgan · Jun 26
Summary
Midway through 2026, healthcare dealmaking and capital markets remain resilient despite macro volatility, with J.P. Morgan pointing to sustained momentum in biotech, biopharma and healthtech.
Pipeline gaps, looming patent cliffs and large pharma cash reserves are pushing companies toward acquisitions, while reopened equity markets are supporting biotech issuance and broader capital deployment.
The biggest transactions include Sun Pharma’s $11.75 billion purchase of Organon, Gilead’s nearly $5 billion acquisition of Tubulis and Angelini Pharma’s $4.1 billion buy of Catalyst Pharmaceuticals.
Cross-border deals and AI-focused transactions are widening the opportunity set, from European medtech consolidation to acquisitions such as CareDX-Naveris and Waystar-Iodine Software.
J.P. Morgan said companies are also using divestitures, take-privates and supply-chain investment to manage regulatory complexity and resilience risks, keeping strategic transactions central through the second half.
Are billion-dollar acquisitions a sustainable cure for big pharma's innovation crisis, or just a temporary fix for looming patent cliffs?
As US-China tech tensions rise, how can healthcare giants secure drug supplies without sacrificing access to critical Chinese innovation?
When a medical AI makes a fatal error, who is held accountable: the doctor, the hospital, or the developer?
2026 Healthcare M&A Report: AI Integration, Private Capital, and Sector-Specific Growth Trends
Overview
In mid-2026, the healthcare M&A landscape is marked by robust deal values and a steady recovery in transaction volumes. Investment activity, excluding entity deals, has surged by 34% year-on-year, though it remains slightly below the five-year average. The number of transactions has also grown by 8% compared to last year, yet still trails historical norms. Despite these volume trends, significant capital continues to flow into the sector, driven by strategic acquisitions and a renewed focus on asset value. This momentum highlights a resilient market, with investors actively seeking opportunities amid ongoing normalization.